Adult-Onset Vitelliform Change: A Different Condition from Childhood Best Disease
Adult-onset vitelliform macular dystrophy (often just called adult vitelliform macular disease, or AVMD) produces a retinal lesion that looks similar to the egg-yolk-like deposit seen in childhood Best disease, but it's a genuinely different condition — it appears later in life, typically in the 30s to 60s, tends to be smaller, and generally follows a milder course. Because the two conditions can look alike on a quick retinal exam, telling them apart matters for setting realistic expectations about prognosis.
Most people with adult-onset vitelliform macular disease notice mild blurring or distortion of central vision, and some are entirely asymptomatic, with the lesion discovered incidentally during a routine eye exam. Compared to childhood Best disease, the vitelliform lesion here tends to be smaller and more centrally located, and it less commonly progresses through the same dramatic multi-stage breakdown pattern. Vision loss, when it happens, is usually gradual and often relatively mild.
The genetics of adult-onset vitelliform macular disease are less uniform than in childhood Best disease. While some cases involve mutations in the same BEST1 gene, many others are linked to mutations in PRPH2 (peripherin-2), a gene involved in maintaining the structure of photoreceptor outer segments. A meaningful proportion of cases have no clearly identified genetic cause on current testing, and inheritance patterns can be less predictable than in the classic childhood form, which is part of why this condition is considered separately.
Diagnosis relies on a combination of retinal imaging and functional testing. Optical coherence tomography identifies the vitelliform lesion and any associated fluid, while fundus autofluorescence highlights the abnormal material accumulating beneath the retina. Electrooculography, which is markedly abnormal in childhood Best disease, is often normal or only mildly reduced in the adult-onset form — this is actually one of the more useful ways of telling the two conditions apart on testing. Genetic testing can identify a BEST1 or PRPH2 mutation in some, though not all, cases.
Most cases of adult-onset vitelliform macular disease are managed with observation, since the condition frequently remains stable or changes only slowly over years. If abnormal blood vessel growth develops beneath the lesion — an uncommon but recognized complication — anti-VEGF injection therapy, the same approach used in several other retinal conditions, can be considered. Low-vision support becomes relevant mainly in the smaller subset of cases where central vision declines meaningfully over time.
The outlook for adult-onset vitelliform macular disease is generally more favorable than for childhood Best disease — vision often remains good or only mildly reduced for many years. Periodic monitoring is still worthwhile, mainly to catch the uncommon complication of abnormal blood vessel growth early, since that particular development responds well to timely treatment.
No, though they can look similar on a retinal photograph. Adult-onset disease appears later in life, tends to be milder, and often has different genetic and test findings — most notably a normal or near-normal electrooculogram, which is typically abnormal in childhood Best disease.
Not necessarily. Many cases remain stable for years, and vision loss, when it does occur, tends to be gradual and often mild.
It's not mandatory, since a meaningful number of cases don't have a clearly identifiable genetic cause on current testing, but it can still be useful for family history discussions where relevant.
A sudden change in central vision, new distortion, or a dark spot appearing quickly warrants prompt evaluation, since it could indicate the uncommon complication of abnormal blood vessel growth, which is treatable if caught early.